Key figures

Net sales 15.1 EUR, million
Gross margin 68,2 %
EBITDA -1.5 EUR, million
Equity ratio 70,0 %

Share Price
Nasdaq Helsinki Stock Exchange

Optomed’s Annual
Report 2023

Read more

Latest releases

Investor events

May 7 - May 7, 2024

Interim Report for 1 January – 31 March 2024

Aug 8 - Aug 8, 2024

Half-Year Financial Report for 1 January – 30 June 2024

Nov 7 - Nov 7, 2024

Interim Report for 1 January – 30 September 2024

Feb 15 - Feb 15, 2024

Financial Statement Bulletin for 1 January – 31 December 2023

Nov 3 - Nov 3, 2023

Interim Report for 1 January – 30 September 2023

Aug 4 - Aug 4, 2023

Half-Year Financial Report for 1 January – 30 June 2023

Optomed as an investment

Optomed is a research and development as well as sales driven medical technology company in expansion phase.

Optomed is one of the leading players in the growing and transforming handheld fundus camera market.

Read more